CTLA4 and head and neck squamous cell carcinoma: In head and neck squamous cell carcinoma, dasatinib acted synergistically with cytotoxic T-lymphocyte associated protein 4 (CTLA4) blockade, suggesting yet another avenue of investigation [164].